Tegaserod maleateProduct ingredient for Tegaserod

Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).^5,8 It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular events in patients.^5,8 Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and whom are considered to be at a lower risk of a cardiovascular event than the broader population.^5,8 Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.⁵ Nevertheless, tegaserod remains un-approved in certain regions.⁷

Despite the relative complications involved in its history of regulatory approval, ever since its first introduction in 2002 tegaserod remains the only therapy for IBS-C that possesses the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and in the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and natural secretions in the gut, among others.^5,1,3,8,6

KEGG Drug

D02730

ChemSpider

10482083

ChEBI

51044

ChEMBL

CHEMBL1516474

Wikipedia

Tegaserod